RVL Pharmaceuticals PLC (FRA:O1P)

€ 0.003 0 (0%) Market Cap: 1.65 Mil Enterprise Value: 38.48 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Q2 2023 RVL Pharmaceuticals PLC Earnings Call Transcript
Aug 14, 2023

€0.402 (-6.07%)

Earnings
Q1 2023 RVL Pharmaceuticals PLC Earnings Call Transcript
May 11, 2023

€0.765 (+3.38%)

Earnings
Q4 2022 RVL Pharmaceuticals PLC Earnings Call Transcript
Mar 20, 2023

€1.22 (+7.96%)

Earnings
Q3 2022 RVL Pharmaceuticals PLC Earnings Call Transcript
Nov 10, 2022

€1.47 (-4.55%)

Earnings
Q2 2022 RVL Pharmaceuticals PLC Earnings Call Transcript
Aug 11, 2022

€1.79 (+16.99%)

Earnings
Q1 2022 RVL Pharmaceuticals PLC Earnings Call Transcript
May 12, 2022

€1.32 (+2.33%)

Earnings
Q4 2021 RVL Pharmaceuticals PLC Earnings Call Transcript
Mar 30, 2022

€1.53 (-4.38%)

Earnings
RVL Pharmaceuticals PLC at Barclays Global Healthcare Conference Transcript
Mar 16, 2022
Osmotica Pharmaceuticals PLC to Discuss Recent UPNEEQ Trends Corporate Call Transcript
Jan 19, 2022
Q3 2021 Osmotica Pharmaceuticals PLC Earnings Call Transcript
Nov 15, 2021

€1.66 (-8.29%)

Earnings
Q2 2021 Osmotica Pharmaceuticals PLC Earnings Call Transcript
Aug 16, 2021

€3.44 (-2.82%)

Earnings
Osmotica Pharmaceuticals PLC Announces Definitive Agreement with Alora Pharmaceuticals LLC Transcript
Jun 25, 2021
Q1 2021 Osmotica Pharmaceuticals PLC Earnings Call Transcript
May 13, 2021

€2.56 (-0.78%)

Earnings
Q4 2020 Osmotica Pharmaceuticals PLC Earnings Call Transcript
Mar 30, 2021

€3.1 (+0.65%)

Earnings
Osmotica Pharmaceuticals PLC at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 09, 2021
Q3 2020 Osmotica Pharmaceuticals PLC Earnings Call Transcript
Nov 10, 2020

€4.96 (+0.81%)

Earnings
Q2 2020 Osmotica Pharmaceuticals PLC Earnings Call Transcript
Aug 11, 2020

€4.82 (+5.24%)

Earnings
Osmotica Pharmaceuticals plc - Special Call Transcript
Jul 09, 2020
Q1 2020 Osmotica Pharmaceuticals PLC Earnings Call Transcript
May 12, 2020

€3.96 (+5.88%)

Earnings
Q4 2019 Osmotica Pharmaceuticals PLC Earnings Call Transcript
Mar 18, 2020

€4.14 (+6.15%)

Earnings
Osmotica Pharmaceuticals PLC at Barclays Global Healthcare Conference Transcript
Mar 10, 2020
Q3 2019 Osmotica Pharmaceuticals PLC Earnings Call Transcript
Nov 15, 2019

€3.22 (-9.55%)

Earnings
Q2 2019 Osmotica Pharmaceuticals PLC Earnings Call Transcript
Aug 08, 2019

€2.78 (-0.71%)

Earnings
Q1 2019 Osmotica Pharmaceuticals PLC Earnings Call Transcript
May 09, 2019

€3.06 (-8.93%)

Earnings
Osmotica Pharmaceuticals plc - Special Call Transcript
May 07, 2019
Q4 2018 Osmotica Pharmaceuticals PLC Earnings Call Transcript
Mar 27, 2019

€5.65 (+4.84%)

Earnings

Osmotica Pharmaceuticals plc - Special Call Transcript

Jul 09, 2020 / 02:00PM GMT

Release Date Price: €5.85 (+5.41%)

Transcript

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the Osmotica Pharmaceuticals Upneeq Approval Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Lisa Wilson, Investor Relations for Osmotica. Please go ahead, ma'am.

Lisa Wilson;In;Site Communications

Inc.,

Thank you, Josh. Welcome to the Osmotica Pharmaceuticals Upneeq Approval Call. This is Lisa Wilson, Investor Relations for Osmotica. With me on today's call are Osmotica's Chief Executive Officer, Brian Markison; Chief Operating Officer, JD Schaub; Dr. David Jacobs, Vice President of Clinical Development and Affairs; and Dr. Chuck Slonim, Adjunct Professor, Ophthalmology, Affiliate Professor Surgery, Division of Plastic Surgery and Clinical Associate Professor, Ophthalmology, at the University of South Florida. This morning, the company issued a press release detailing the Upneeq approval. This press release and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.